Other

Cv Molecular Therapeutics, Inc.

University of British Columbia

British Columbia Cancer Agency Branch

Simon W. Rabkin

Gerald Krystal

Simon W Rabkin

Raymond John Andersen

Christopher J Ong

Alice Mui

David Williams

Lu Yang

This invention provides a method for identifying allosteric modulators of a SHIP polypeptide, wherein said SHIP polypeptide is contacted with a test compound, and wherein said SHIP polypeptide comprises an allosteric site selected from the group consisting of a SHIP C2 domain and a SHIP PH domain.

Methods for identifying allosteric modulators of ship polypeptides

The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.

Ship 1 modulators

The present invention relates to a method of reducing cell death in a warm-blood animal wherein said cell death associated with a neurodegenerative disorder, an immune disease, a neoplastic disorder, an inflammatory disorder, or a viral disease. The method comprises administering to said animal a therapeutically effective amount of a peptide comprising amino acid sequence: Ser-Val-Asp-Val-Glu-Tyr.

Peptides and their use to ameliorate cell death

There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, obtained from streptokinase suitable for use in the amelioration of cell death and methods related thereto.

Novel SH2-containing inositol-phosphatase which has a src homology 2 (SH2) domain and exhibits phosphoIns-5-ptase activity, and nucleic acid molecules encoding the novel protein are disclosed. The invention also relates to methods for identifying substances which affect the binding of the protein to Shc and/or its phosphoIns-5-ptase activity and methods for screening for agonists or antagonists of the binding of the protein and Shc.

SH2-containing inositol-phosphatase

There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, derived from streptokinase suitable for use in the amelioration of cell death and methods related thereto.

A novel, inexpensive, highly sensitive and quantitative assay for measuring protein in solution based on the capacity of protein to bind silver is described. In this procedure, protein samples are first treated with glutaraldehyde and then exposed to ammoniacal silver. After a specified time, the reaction is terminated by the addition of sodium thiosulfate and the optical density measured at 420 nm. The useful range of the assay for the majority of standard proteins tested lies between 15 and 2000 ng. This represents a 100-fold increase in sensitivity over the Coomassie Brilliant Blue dye binding procedure. There is little or no interference from carbohydrates, non-ionic detergents or ethanol. Pretreatment of protein samples with Bio-Gel P-2 to remove salts, thiol agents, EDTA and SDS, makes this procedure compatible with most commonly used buffers.

Growing community of inventors

Vancouver, Canada

Gerald Krystal